Orna Therapeutics

Viva Roma! Heading to the 31st Annual European Society of Gene and Cell Therapy Congress? Come check out Poster Session 1, where Dan Egan, PhD Director, Gene Editing, will present research on Orna’s in vivo hematopoietic stem cell gene editing approach for the treatment of beta-hemoglobinopathies. Join us to learn more about how we’re pioneering the next chapter of safe and effective in vivo therapies with leading circular RNA (oRNA?) and unprecedented lipid nanoparticle (LNP) delivery solutions. https://lnkd.in/e_FEnzpu #ESGCT2024 #GeneTherapy #GeneEditing #Biotech

We believe in fueling curiosity, creativity and innovation, and are proud to contribute to building a brighter, equitable future for girls in science. Recently Orna had the pleasure of collaborating with Science Club for Girls to support the next generation of female scientists by donating laptops. These devices will empower young minds through the Club’s free experiential programs in the Greater Boston area, providing tools and hands-on learning opportunities to explore STEM, ignite confidence, and connect with women-in-STEM mentors to foster their scientific interests and academic goals. Take a moment to learn more here about Science Club for Girls and its impact. https://lnkd.in/eE8Vj2wB #DiversityInSTEM #WomenInSTEM #GirlsInSTEM

This Thursday, September 19th, Orna CSO Robert Mabry will be speaking at the 9th Annual CAR-TCR Summit Series. Join us as we present the latest data on circular RNA therapy for the treatment of B cell malignancies, and participate in a panel discussion highlighting the potential for the next generation of in vivo #celltherapy. #CARTCR2024

We’re thrilled to welcome Nobel Laureate Carolyn Bertozzi to our Scientific Advisory Board as Co-Chair alongside Tom Barnes. Dr. Bertozzi’s expertise as a pioneer in emerging technologies will be invaluable as we advance a new category of panCAR? in vivo CAR RNA medicines. We look forward to working with Drs. Bertozzi and Barnes to realize the full potential of RNA therapeutics for cancer and autoimmune diseases. ? Read more here: https://lnkd.in/eMbF9Y4V #RNA #Biotech #BioPharma #Science

Calling all Staff Accountants: Orna's Finance team is hiring! This is a great opportunity to break into biotech and gain broad experience. Know anyone who might be interested? Apply here: https://lnkd.in/eQPiUCtA #hiring

Orna’s acquisition of ReNAgade Therapeutics is a testament to our dedication to unlocking an entirely new and promising class of RNA-based medicines. Together, we are more than the sum of our platforms — with the potential to drive better efficacy and patient outcomes compared to current cell therapy and gene editing approaches — addressing massive unmet needs in diseases such as sickle cell and thalassemia. Read more here: https://lnkd.in/eYHYAfkf #RNA #Biotech #Biopharma

In case you missed this morning’s news, Orna acquired ReNAgade Therapeutics — a significant step forward for the field of RNA-targeted therapies and for modalities with continued unmet need including CAR therapy and gene editing. We are leveraging deep knowledge and a range of highly innovative capabilities to solve the most pressing challenges in drug development today. ? Read more here: https://lnkd.in/eYHYAfkf #RNA #Biotech #Biopharma #Science

Today marks a new chapter for Orna and for the future of RNA-based medicines as we announce our acquisition of ReNAgade Therapeutics. This strategic move unifies two industry-leading circles with the knowhow to significantly expand circular RNA engineering and delivery technologies and advance in vivo CAR and gene editing approaches for a range of diseases. Join us in welcoming Amit Munshi as Chief Executive Officer as Tom Barnes, PhD transitions to Co-Chair of our Scientific Advisory Board. Read more here: https://lnkd.in/eYHYAfkf #Biopharma #Science #Biotech

Orna is Baltimore-bound! Be sure to catch us at #ASGCT2024, where we’ll present several posters highlighting our industry-leading circular RNA technology (oRNA). For more info:?https://lnkd.in/dHgkVjV

Thank you Matthew Pillar and Anna Rose Welch for a great Business of Biotech conversation with our CEO Tom Barnes, covering the journey of an academic in biotech and the immense potential of circles in #RNA??? Listen to the full conversation on your favorite podcast platform or on the website here:? https://lnkd.in/eT-qwEzt